Article
Acinetobacter baumannii response to cefiderocol challenge in human urine
24 May 2022
Abstract excerpt
Abstract Cefiderocol (CFDC) is a novel chlorocatechol-substituted siderophore antibiotic approved to treat complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-acquired pneumonia (HAP/VAP). Previous work determined that albumin-rich human fluids increase the minimum inhibitory concentration (MICs) of Acinetobacter baumannii against CFDC and reduce the expression of genes related to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
